Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Penumbra, Inc. (PEN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that together outline Penumbra’s financial condition, major corporate events and obligations as a NYSE-listed issuer.
Among the most significant recent filings is a Form 8-K dated January 15, 2026, in which Penumbra reports entry into an Agreement and Plan of Merger with Boston Scientific Corporation and a Boston Scientific subsidiary. The filing describes the structure of the merger consideration, the mix of cash and Boston Scientific common stock, and the conditions required for closing. It also states that, if the merger is consummated, Penumbra’s securities will be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934 as promptly as practicable after the effective time.
Other Form 8-K filings highlighted here include results of operations and financial condition for specific quarters, where Penumbra furnishes earnings press releases as exhibits. These filings discuss revenue growth, gross margin, operating margin and the use of non-GAAP measures such as constant currency revenue, non-GAAP income from operations and adjusted EBITDA. The company explains how these non-GAAP metrics are calculated and why management considers them useful for assessing underlying business performance.
Additional 8-Ks address corporate governance and leadership changes, such as the appointment of a new company president and related compensation arrangements. These filings provide detail on board and executive decisions, equity awards and related person transactions, all within the framework of SEC disclosure requirements.
Through this page, users can follow Penumbra’s formal reporting on material events, financial results and the proposed merger with Boston Scientific. Stock Titan’s platform associates each filing with AI-powered summaries designed to explain the core points of lengthy documents, helping readers quickly understand items such as merger terms, earnings highlights, and key governance changes without having to parse every line of the underlying text.
For deeper research, investors can review the full text of Penumbra’s 10-K and 10-Q reports via the SEC’s EDGAR system, while using the summaries and context on this page as a guide to the most important disclosures affecting PEN and its anticipated transition to a wholly owned subsidiary of Boston Scientific.
Penumbra, Inc. sent letters urging stockholders to vote FOR the proposed merger with Boston Scientific and reminding recipients that failing to vote is treated the same as a vote against the Merger. The company notes the Proxy Statement/Prospectus on Form S-4 was declared effective on April 1, 2026 and that a Special Meeting of stockholders is scheduled for May 6, 2026. The letters instruct holders to vote by Internet, telephone, or by returning a proxy card, and identify Company and Parent sources for free copies of SEC filings. The communication includes standard forward-looking statements and a list of material risks described in the Proxy Statement/Prospectus.
Boston Scientific Corporation discussed Q1 2026 results and reiterated that its announced acquisition of Penumbra is expected to close in the second half of 2026, subject to the Penumbra shareholder vote on May 6th/7th and receipt of remaining regulatory clearances. The company said guidance excludes the Penumbra transaction and noted a recent tuck-in acquisition of Valencia Technologies.
The call emphasized growth in Interventional Oncology, continued prioritization of strategic tuck-in M&A and share repurchases, and that all revenue references on the call were organic and exclude certain recent acquisitions or divestitures.
The Company Penumbra, Inc. is soliciting votes in support of the proposed merger with Boston Scientific Corporation. The Board unanimously recommends shareholders vote FOR the Merger at a Special Meeting to be held on May 6, 2026. A Form S-4 proxy statement/prospectus was declared effective on April 1, 2026.
Stockholders are urged to read the Proxy Statement/Prospectus and may obtain free copies from the SEC or the companies' investor websites.
Penumbra Inc director Harpreet Grewal reported an open-market sale of 100 shares of common stock at $328.22 per share on April 2, 2026. After this transaction, Grewal directly holds 8,719 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan, and a portion of the remaining shares is subject to vesting.
Penumbra, Inc. submitted a Rule 144 notice listing specific Common Stock transactions. The excerpt shows a 100-share lot linked to Fidelity Brokerage Services LLC with a numeric entry $32,822.00 and a separate entry showing 186 shares associated with Grewal Harpreet on 01/06/2026 with $58,151.04. Dates visible include 04/02/2026.
Penumbra, Inc. is proposing to be acquired by Boston Scientific Corporation pursuant to an Agreement and Plan of Merger dated January 14, 2026, under which Penumbra will become a wholly owned subsidiary of Boston Scientific. Each issued and outstanding Penumbra share (other than excluded or dissenting shares) will convert into the right to receive either $374.00 in cash or 3.8721 Boston Scientific Shares, subject to a proration mechanism that allocates 73.26% of shares to cash consideration and 26.74% to stock consideration.
The parties valued the consideration at $374.00 per Penumbra share at announcement. Based on shares outstanding as of March 27, 2026, Boston Scientific expects to issue approximately 43,866,267 Boston Scientific Shares and former Penumbra holders would own ~2.87% of Boston Scientific post-close. The special meeting of Penumbra stockholders is scheduled for May 6, 2026, and the proxy/prospectus contains detailed election procedures, regulatory conditions, termination fees and risk factors.
Penumbra Inc Schedule 13G/A: The Vanguard Group files an amendment reporting 0 shares beneficially owned—0% of Common Stock following an internal realignment.
The amendment explains that, effective January 12, 2026, certain Vanguard subsidiaries and business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim on 03/27/2026.
Penumbra Inc President Shruthi Narayan reported a routine tax-withholding share disposition. On the vesting of restricted stock units, 117 shares of common stock were withheld by the company to satisfy tax obligations at an indicated value of $336.18 per share. After this non-market event, Narayan directly holds 30,755 shares of Penumbra common stock, and a portion of these shares remains subject to vesting.
Penumbra Inc executive Johanna Roberts had 186 shares of Common Stock withheld by the company to cover taxes on vesting restricted stock units. The shares were valued at $336.18 per share for this tax-withholding transaction. After this non-market disposition, she directly holds 67,298 shares of Penumbra Common Stock.
This event reflects routine tax withholding related to equity compensation rather than an open-market sale or discretionary trading decision.
Penumbra Inc Chief Financial Officer Maggie Yuen reported a routine tax-related share disposition. The company withheld 186 shares of common stock at $336.18 per share to satisfy tax obligations tied to vesting restricted stock units. After this withholding, she directly holds 18,167 common shares.